A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 30 Jan 2023
At a glance
- Drugs GLPG 3970 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Acronyms SEA TURTLE
- Sponsors Galapagos NV
Most Recent Events
- 14 Jul 2021 Results presented in the Galapagos NV Media Release.
- 30 Jun 2021 Status changed from active, no longer recruiting to completed.
- 14 Apr 2021 Status changed from recruiting to active, no longer recruiting.